FOXA1 has multiple impact on PCa, including (1) controls the morphogenesis and cell differentiation of prostate (Gao et al., 2005); (2) facilitates AR transactivation which is essential for PCa proliferation and survival (Zhao, Tindall & Huang, 2014); (3) inhibits PCa progress towards neuroendocrine prostate cancer, whose prognosis is worse (Kim et al., 2017); (4) downregulates TGF-β signaling and thus suppresses castration-resistant prostate cancer progression (Song et al., 2019a). Here, AR is linked to prostate cancer.